Clinical Trial Update: A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients

View source ↗

Summary

A real-world study evaluating remibrutinib for chronic spontaneous urticaria, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• Remibrutinib (remibrutinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Spontaneous Urticaria | Status: RECRUITING